NO1A Stock Overview
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Navidea Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.067 |
| 52 Week High | US$0.30 |
| 52 Week Low | US$0.032 |
| Beta | 1.53 |
| 1 Month Change | 0% |
| 3 Month Change | 46.15% |
| 1 Year Change | -68.03% |
| 3 Year Change | -96.26% |
| 5 Year Change | n/a |
| Change since IPO | -99.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| NO1A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -1.2% |
| 1Y | -68.0% | -15.4% | 1.2% |
Return vs Industry: NO1A underperformed the German Biotechs industry which returned -21.4% over the past year.
Return vs Market: NO1A underperformed the German Market which returned 7% over the past year.
Price Volatility
| NO1A volatility | |
|---|---|
| NO1A Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: NO1A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NO1A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 13 | n/a | www.navidea.com |
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
Navidea Biopharmaceuticals, Inc. Fundamentals Summary
| NO1A fundamental statistics | |
|---|---|
| Market cap | €5.04m |
| Earnings (TTM) | -€8.05m |
| Revenue (TTM) | €556.81 |
9,049x
P/S Ratio-0.6x
P/E RatioIs NO1A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NO1A income statement (TTM) | |
|---|---|
| Revenue | US$610.00 |
| Cost of Revenue | US$50.04k |
| Gross Profit | -US$49.43k |
| Other Expenses | US$8.77m |
| Earnings | -US$8.81m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | -8,102.62% |
| Net Profit Margin | -1,444,993.44% |
| Debt/Equity Ratio | -41.9% |
How did NO1A perform over the long term?
See historical performance and comparison